Skip to main content
. 2017 Feb 7;116(6):802–810. doi: 10.1038/bjc.2017.8

Figure 3.

Figure 3

Frequency of the EGFR p.T790M mutation (green: T790M− red T790M+) after progression to thyrosine kinase inhibitors (TKIs) in the serum and plasma cfDNA of EGFR-mutated patients evaluated with SiRe panel NGS.A full colour version of this figure is available at the British Journal of Cancer journal online.

HHS Vulnerability Disclosure